Currently out of the existing stock ratings of Aydin Huseynov, 49 are a BUY (85.96%), 8 are a HOLD (14.04%).

Aydin Huseynov

Work Performance Price Targets & Ratings Chart

Analyst Aydin Huseynov, currently employed at LADENBURG, carries an average stock price target met ratio of 29.76% that have a potential upside of 46.6% achieved within 108 days.

Aydin Huseynov’s has documented 106 price targets and ratings displayed on 23 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on MRKR, Marker Therapeutics at 20-Oct-2024.

Wall Street Analyst Aydin Huseynov

Analyst best performing recommendations are on INO (INOVIO PHARMACEUTICALS).
The best stock recommendation documented was for INO (INOVIO PHARMACEUTICALS) at 5/21/2020. The price target of $336 was fulfilled within 35 days with a profit of $165.12 (96.63%) receiving and performance score of 27.61.

Average potential price target upside

of $180.5 (47.73%) on PALI (PALISADE BIO).
of $117.24 (79.66%) on INO (INOVIO PHARMACEUTICALS).
of $73.76 (12.98%) on REGN (REGENERON PHARMACEUTICALS).

CALA Calithera Biosciences INCY yte INO Inovio Pharmaceuticals NKTR Nektar Therapeutics REGN Regeneron Pharmaceuticals SLS Sellas Life Sciences Group SPRB Spruce Biosciences VYGR Voyager Therapeutics NXTC NextCure ALLR Allarity Therapeutics ATHE Alterity Therapeutics Ltd CMPX Compass Therapeutics PCSA Processa Pharmaceuticals TRIL Trillium Therapeutics PALI Palisade Bio CRVS Corvus Pharmaceuticals CGTX Cognition Therapeutics TPST Tempest Therapeutics CAPR Capricor Therapeutics MRKR Marker Therapeutics ACRV Acrivon Therapeutics, Common Stock ALRN Aileron Therapeutics IONS Ionis Pharmaceuticals

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Jonathan Chang (LEERINK)